Department of Pediatric Intensive Care, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Pediatric Nephrology, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlands.
Crit Care Med. 2019 Nov;47(11):e893-e901. doi: 10.1097/CCM.0000000000003973.
Acute kidney injury requiring continuous renal replacement therapy is a serious treatment-related complication in pediatric cancer and hematopoietic stem cell transplant patients. The purpose of this study was to assess epidemiology and outcome of these patients requiring continuous renal replacement therapy in the PICU.
A nationwide, multicenter, retrospective, observational study.
Eight PICUs of a tertiary care hospitals in the Netherlands.
Pediatric cancer and hematopoietic stem cell transplant patients (cancer and noncancer) who received continuous renal replacement therapy from January 2006 to July 2017 in the Netherlands.
None.
Of 1,927 PICU admissions of pediatric cancer and hematopoietic stem cell transplant patients, 68 of 70 evaluable patients who received continuous renal replacement therapy were included. Raw PICU mortality was 11.2% (216/1,972 admissions). PICU mortality of patients requiring continuous renal replacement therapy was 54.4% (37/68 patients). Fluid overload (odds ratio, 1.08; 95% CI, 1.01-1.17) and need for inotropic support (odds ratio, 6.53; 95% CI, 1.86-23.08) at the start of continuous renal replacement therapy were associated with PICU mortality. Serum creatinine levels increased above 150% of baseline 3 days before the start of continuous renal replacement therapy. Urine production did not reach the critical limit of oliguria. In contrast, body weight (fluid overload) increased already 5 days prior to continuous renal replacement therapy initiation.
PICU mortality of pediatric cancer and hematopoietic stem cell transplant patients requiring continuous renal replacement therapy is sadly high. Fluid overload at the initiation of continuous renal replacement therapy is the most important and earliest predictor of PICU mortality. Our results suggest that the most commonly used criteria of acute kidney injury, that is, serum creatinine and urine production, are not useful as a trigger to initiate continuous renal replacement therapy. This highlights the urgent need for prospective studies to generate recommendations for effective therapeutic interventions at an early phase in this specific patient population.
需要持续肾脏替代治疗的急性肾损伤是儿科癌症和造血干细胞移植患者严重的治疗相关并发症。本研究的目的是评估在儿科重症监护病房(PICU)接受持续肾脏替代治疗的这些患者的流行病学和结局。
一项全国性、多中心、回顾性、观察性研究。
荷兰 3 家三级护理医院的 8 个 PICU。
2006 年 1 月至 2017 年 7 月期间在荷兰接受持续肾脏替代治疗的儿科癌症和造血干细胞移植患者(癌症和非癌症)。
无。
在 1927 例儿科癌症和造血干细胞移植患者的 PICU 入院中,对 70 例可评估患者中的 68 例接受了连续肾脏替代治疗,其中包括 68 例。原始 PICU 死亡率为 11.2%(1972 例入院中有 216 例)。需要持续肾脏替代治疗的患者的 PICU 死亡率为 54.4%(68 例患者中有 37 例)。开始连续肾脏替代治疗时出现液体超负荷(优势比,1.08;95%可信区间,1.01-1.17)和需要正性肌力支持(优势比,6.53;95%可信区间,1.86-23.08)与 PICU 死亡率相关。开始连续肾脏替代治疗前 3 天血清肌酐水平升高至基线的 150%以上。尿液生成未达到少尿的临界限制。相比之下,体重(液体超负荷)在开始连续肾脏替代治疗前 5 天就已经增加。
需要持续肾脏替代治疗的儿科癌症和造血干细胞移植患者的 PICU 死亡率令人遗憾地很高。开始连续肾脏替代治疗时的液体超负荷是 PICU 死亡率的最重要和最早的预测因素。我们的结果表明,最常用的急性肾损伤标准,即血清肌酐和尿液生成,作为开始连续肾脏替代治疗的触发因素并不有用。这突出表明迫切需要进行前瞻性研究,以便为该特定患者人群的早期阶段提供有效的治疗干预建议。